ProtoKinetix, Incorporated

What they do

ProtoKinetix researches AFGPs (anti-freeze glycoproteins), trademarked as AAGPs, for potential health care applications. The company has no revenues and operates by hiring outside consultants for management, strategic planning, and daily operations. It is focused on commercial validation of AAGP and seeks industry partners and institutional collaborations to advance research.

Revenue drivers

• AAGP molecule licensing or partnerships — The company has no revenues from any source; future revenue would depend on licensing or commercializing AAGP, but no such agreements are disclosed.

Recent performance

For fiscal year 2025, ProtoKinetix reported a net loss of $393,650, compared to a net loss of $364,188 in 2024. Operating expenses were $393,650 in 2025, including $177,610 in professional fees, $106,613 in research and development, and $58,135 in general and administrative costs. No revenues were recorded in either 2025 or 2024. As of December 31, 2025, the company had cash of $1,118, total assets of $483,374, and negative working capital of $183,266.

Strategy

Management states it is directing efforts toward commercial validation of AAGP and seeking industry partners to move research forward. The company has scaled back new research and is focusing on leveraging prior study findings through institutional collaborations. It continues to maintain existing patent families while reducing general and administrative spending on marketing and press releases. Professional fees in 2025 included legal work for shareholder voting on increasing authorized shares and a patent portfolio valuation. The company acknowledges it does not have sufficient capital to meet short-term cash flow projections.

Risks

• No revenue or operating history — ProtoKinetix has no revenues and a very limited operating history, making it dependent on outside funding to complete development and commercialization.
• Going concern and liquidity — As of December 31, 2025, the company had $1,118 in cash and negative working capital of $183,266, and management states it does not believe it has sufficient capital to meet short-term cash flow projections.
• Dependence on key personnel — The company relies on its management team and advisory board, and does not expect to obtain key man life insurance for any members of management.
• Uncertainty of product development — The company's ability to generate revenues from its intellectual property depends on factors including available funds to complete development, test and refine products, and commercialize them, with no assurance of success.

Outlook

Management states that the company will need additional working capital to continue medical research or be successful in future business activities. It is focused on finding industry partners to advance AAGP research and leveraging positive study findings through targeted investments. There is no assurance that the company will be able to raise capital from outside sources in sufficient amounts to fund its business.